(Adds details, updates share price move) COPENHAGEN, Oct 29 (Reuters) - Drug maker Novo Nordisk raised its forecast for sales and operating profit for the full year on Friday after stronger than expected sales in the third quarter, sending its shares to a record high. The world’s biggest producer of diabetes drugs now expects both sales and operating growth of between 12% and 15%, up from 10-13% and 9-12%, respectively. Novo shares were up 2% at 703.7 Danish crowns by 1408 GMT, having risen as high as 715.9 crowns, surpassing a previous peak of 694 crowns set on Wednesday. “The updated outlook is reflecting higher than expected Ozempic market share gains, GLP-1 market growth and obesity care sales, mainly in the United States,” the company said in a statement. Ozempic is Novo’s new once-weekly injectable treatment. It belongs to the GLP-1 class of drugs, which imitate an intestinal hormone that stimulates insulin production. Group sales rose 15% between July and September, above the 12% increase expected by analysts in a poll gathered by Refinitiv. Sales were helped by demand for Wegovy, which was approved by authorities in the United States in June. The drug is a GLP-1 analogue, which lowers appetite and increases feelings of fullness by imitating a gut hormone that stimulates insulin production. Operating profit rose 19%, compared with 14% growth expected by analysts. The company will publish a full set of quarterly results on Nov. 3. (Reporting by Jacob Gronholt-Pedersen; Editing by Jane Merriman and David Holmes)